MZMin Zheng

Min Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Min Zheng has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Long Huang

    State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China

    6 shared publications
  • Hui Ding

    State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China

    3 shared publications
  • Li He

    State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China

    3 shared publications
  • Yan-Hong Yu

    Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China

    3 shared publications
  • Hui-Yun Wang

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

    2 shared publications
  • Hui‐Yun Wang

    State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong P.R. China

    2 shared publications

Latest Publications

  • Open Access

    KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a

    by L Huang, H-Y Wang, J-D Li, J-H Wang, Y Zhou, R-Z Luo, J-P Yun, Y Zhang, W-H Jia, M Zheng

    Karyopherin alpha 2 (KPNA2), a member of the karyopherin family, has a central role in nucleocytoplasmic transport and is overexpressed in many cancers. Our previous study identified KPNA2 as significantly upregulated in epithelial ovarian carcinoma (EOC), correlating with poor survival of patients. However, the precise mechanism of this effect remains unclear. The aim of the present study was to examine the role of KPNA2 in the proliferation and tumorigenicity of EOC cells, and its clinical significance in tumor progression. Real-time quantitative RT-PCR analysis revealed high expression levels of KPNA2 in 162 out of 191 (84.8%) fresh EOC tissues, which was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage, differentiation, histological type, recurrence, and prognosis of EOC patients. Our results showed that upregulation of KPNA2 expression significantly increased the proliferation and tumorigenicity of EOC cells (EFO-21 and SK-OV3) in vitro and in vivo, by promoting cell growth rate, foci formation, soft agar colony formation, and tumor formation in nude mice. By contrast, knockdown of KPNA2 effectively suppressed the proliferation and tumorigenicity of these EOC cells in vitro and in vivo. Our results also indicated that the molecular mechanisms of the effect of KPNA2 in EOC included promotion of G1/S cell cycle transition through upregulation of c-Myc, enhanced transcriptional activity of c-Myc, activation of Akt activity, suppression of FOXO3a activity, downregulation of cyclin-dependent kinase (CDK) inhibitor p21Cip1 and p27Kip1, and upregulation of CDK regulator cyclin D1. Our results show that KPNA2 has an important role in promoting proliferation and tumorigenicity of EOC, and may represent a novel prognostic biomarker and therapeutic target for this disease.


  • Open Access

    Overexpression of Karyopherin 2 in Human Ovarian Malignant Germ Cell Tumor Correlates with Poor Prognosis

    by Li He, Hui Ding, Jian-Hua Wang, Yun Zhou, Li Li, Yan-Hong Yu, Long Huang, Wei-Hua Jia, Musheng Zeng, Jing-Ping Yun, et al.

    The aim of this study was to identify a biomarker useful in the diagnosis and therapy of ovarian malignant germ cell tumor (OMGCT). The karyopherin 2 (KPNA2) expression in OMGCT and normal ovarian tissue was determined by standard gene microarray assays, and further validated by a quantitative RT-PCR and immunohistochemistry. The correlation between KPNA2 expression in OMGCT and certain clinicopathological features were analyzed. Expression of SALL4, a stem cell marker, was also examined in comparison with KPNA2. KPNA2 was found to be over-expressed by approximately eight-fold in yolk sac tumors and immature teratomas compared to normal ovarian tissue by microarray assays. Overexpression was detected in yolk sac tumors, immature teratomas, dysgerminomas, embryonal carcinomas, mature teratomas with malignant transformation and mixed ovarian germ cell tumors at both the transcription and translation levels. A positive correlation between KPNA2 and SALL4 expression at both the transcription level (R = 0.5120, P = 0.0125), and the translation level (R = 0.6636, PP = 0.02). The 5-year overall survival (OS) and DFS rate for KPNA2-low expression patients (88% and 79%, n = 48) were significantly higher than the OS and DFS rate for KPNA2-high expression patients (69% and 57.1%, n = 42)(P = 0.0151, P = 0.0109, respectively). The 5-year OS and DFS rate for SALL4-low expression patients (84% and 74%, n = 62) was marginally significantly higher than the high expression patients (78.6% and 71.4%, n = 28)(P = 0.0519, P = 0.0647, respectively). KPNA2 is a potential candidate molecular marker and important prognostic marker in OMGCT patients.


  • Open Access

    Downregulation of Six MicroRNAs Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix

    by Long Huang, Jia-Xin Lin, Yan-Hong Yu, Mei-Yin Zhang, Hui-Yun Wang, Min Zheng

    Small cell carcinoma of the cervix (SCCC) is very rare, and due to the long time period required to recruit sufficient numbers of patients, there is a paucity of information regarding the prognostic factors associated with survival. MicroRNAs (miRNAs) have been used as cancer-related biomarkers in a variety of tumor types, and the objective of this study was to determine whether microRNA expression profiles can predict clinical outcome in SCCC. Forty-four patients with SCCC who underwent radical hysterectomy between January 2000 and October 2009 were enrolled. Using the GeneCopoeia All-in-One™ Customized Human qPCR Primer Array, the expression profiles of 30 miRNAs associated with tumor metastasis was obtained from the formalin-fixed paraffin embedded samples of all 44 patients. Seven miRNAs, has-let-7c, has-miR-10b, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p were significantly down-regulated in advanced stage SCCCpatients (FIGO IB2-IV) compared to early stage SCCC patients (FIGOIB1). Among, downregulation of six miRNAs, has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p were significantly associated with lymph node metastasis and reduced survival in SCCC. Kaplan–Meier survival analyses revealed that SCCC patients with low expression of has-miR-100 (P = 0.019) and has-miR-125b (P = 0.020) projected a significant tendency towards poorer prognosis. This study demonstrates that downregulation of 7 miRNA associated with advanced stage, 6 miRNAs with metastasis and 2 with poor prognosis in SCCC. Functional analysis of these miRNAs may enhance our understanding of SCCC, as altered expression of specific miRNAs may regulate the metastatic pathway and provide novel targets for therapy.


  • Identification of a 7-gene signature that predicts relapse and survival for early stage patients with cervical carcinoma

    by Long Huang, Min Zheng, Qing-Ming Zhou, Mei-Yin Zhang, Yan-Hong Yu, Jing-Ping Yun, Hui-Yun Wang

    There is no gene signature for predicting relapse and survival of cervical cancer with early stage currently. In this study, we investigate whether gene expression profiling of cervical cancer could be used to predict the prognosis of patient. A series of 100 primary cervical cancer patients who underwent radical hysterectomy between January 2001 and October 2006 were analyzed for gene expression profiles by using a custom oligonucleotide microarray containing probes for 1440 human tumor-related gene transcripts. Supervised analysis of gene expression data identified 19 genes that exhibited differential expression between cervical cancer and normal cervix. Then, all 100 patients were divided into the training (n = 50) and testing sets (n = 50). Using Cox regression and risk-score analysis, we identified a 7-gene (UBL3, FGF3, BMI1, PDGFRA, PTPRF, RFC4, and NOL7) signature for predicting relapse of patient in the training set. The 7-gene signature was validated by the testing set (sensitivity, 84.6%; specificity, 91.9%; positive predictive value, 78.6%; negative predictive value, 94.4%). Patients with high-risk 7-gene signature had poor relapse-free survivals (RFS) than patients with low-risk 7-gene signature in both training set (P = 0.026) and testing set (P = 0.042). Multivariate analysis showed that the FIGO stage and 7-gene signature are independent prognostic factors associated with RFS of cervical cancer patients. The 7-gene signature can predict cancer recurrence and survival of cervical cancer patients. This may have prognostic or therapeutic implications for the future management of cervical cancer patients.


  • Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB–IIB cervical carcinoma: A retrospective study of 288 patients

    by Min Zheng, Long Huang, Ji‐Hong Liu, Ying Xiong, Jun‐Dong Li, Xin Huang, Li He, Yu‐Feng Ren, Hui‐Yun Wang

    Background and Objectives: The aim of this study was to evaluate type II radical hysterectomy with or without adjuvant therapy as a treatment for patients with pelvic lymph node metastasis (PLNM) and stage IB–IIB cervical carcinoma.Methods: A total of 288 patients with stage IB–IIB cervical carcinoma and confirmed PLNM who underwent a type II radical hysterectomy between 1995 and 2005 were retrospectively evaluated.Results: The 5‐year overall survival (OS) rate for this cohort was 65.6%, and independent prognostic factors identified for PLNM patients included a non‐squamous cell histological subtype and parametrial involvement. Survival differences between patients that received or did not receive adjuvant treatment were also evaluated, and the 5‐year OS and DFS rates for patients who did not receive adjuvant therapy (47 and 41.4%, respectively) were much lower than the rates for patients who did receive adjuvant therapies (67.7 and 59.4%, respectively). However, these differences were not statistically significant (OS, P = 0.057; DFS, P = 0.080).Conclusions: Type II radical hysterectomy, in combination with adjuvant therapies, is an efficient treatment for PLNM patients with stage IB–IIB cervical cancer. J. Surg. Oncol. 2011; 104:480–485.


  • Evaluation of the effects of type II radical hysterectomy in the treatment of 960 patients with stage IB–IIB cervical carcinoma: A retrospective study

    by Min Zheng, Long Huang, Li He, Hui Ding, Hui‐Yun Wang, Li‐Min Zheng

    Background and Objectives: This retrospective study evaluated the feasibility and effectiveness of type II radical hysterectomies alone, or in combination with adjuvant treatment, for the treatment of patients with stage IB–IIB cervical cancer with or without high‐risk factors.Methods: A total of 960 stage IB–IIB patients who underwent type II radical hysterectomies between 1995 and 2004 were enrolled and retrospectively analyzed.Results: Uterine corpus invasion, parametrial margin involvement, and pelvic lymph node metastasis were identified as independent prognostic factors for stage IB patients. For stage IIA–IIB patients, histologic type, parametrial margin involvement, and pelvic lymph node metastasis were identified as independent prognostic factors. The 5‐year overall survival (OS) rates for patients with stage IB versus stage IIA–IIB cervical carcinomas were 88.4% and 78.5%, respectively. Moreover, adjuvant radiotherapy and chemotherapy improved the 5‐year OS rates of stage IIA–IIB patients associated with high‐risk factors. The overall recurrence rate for this cohort was 14.4%.Conclusions: Our findings show that type II radical hysterectomy is a feasible treatment option for stage IB–IIB cervical carcinoma patients. Furthermore, type II radical hysterectomy combined with adjuvant post‐operative therapy improves the OS of women with high‐risk factors for cervical carcinoma. J. Surg. Oncol. 2011; 103:435–441.


  • Overexpression of Karyopherin-2 in Epithelial Ovarian Cancer and Correlation With Poor Prognosis

    by Min Zheng, Li Tang, Long Huang, Hui Ding, Wen-Ting Liao, Mu-Sheng Zeng, Hui-Yun Wang

    OBJECTIVES: To evaluate karyopherin 2 (KPNA2) as a biomarker for epithelial ovarian cancer. METHODS: A candidate oncogene, KPNA2, was identified in gene microarray assays of epithelial ovarian cancer tissues compared with normal human ovarian surface epithelial tissues. Differences in expression were further validated by real-time polymerase chain reaction and Western blotting. KPNA2 expression patterns in epithelial ovarian cancer tissues were determined using immunohistochemistry and were compared with specific clinicopathologic features of the patient specimens analyzed. Factors associated with patient survival were also statistically analyzed. RESULTS: KPNA2 was found to be upregulated approximately eightfold in epithelial ovarian cancer tissues compared with human ovarian surface epithelial tissues, and overexpression was detected at the level of both transcription and translation. Immunohistochemical assays detected positive KPNA2 expression (++ or +++) in 50 of 102 (49.0%) epithelial ovarian cancer specimens, whereas negative KPNA2 expression (− or +) was observed in all of the human ovarian surface epithelial tissues analyzed. KPNA2 overexpression was also found to be significantly associated with specific histologic type, an advanced stage, a high histologic grade, and tumor recurrence (P<.05). The 5-year overall survival rate for KPNA2-negative compared with KPNA2-positive patients was 73.1% and 60.5%, respectively (P<.05). CONCLUSION: KPNA2 may play an important role in the development, differentiation, and carcinogenesis of epithelial ovarian cancer and therefore could be an indicator of poor prognosis for patients with epithelial ovarian cancer. LEVEL OF EVIDENCE: II